The clinical characteristics,survival and prognosis of 27 mantle cell lymphoma patients
- VernacularTitle:套细胞淋巴瘤27例临床特征及生存预后分析
- Author:
Shuhua YI
;
Gang AN
;
Dehui ZOU
;
Junyuan QI
;
Yaozhong ZHAO
;
Zengjun LI
;
Lugui QIU
- Publication Type:Journal Article
- Keywords:
mantle cell lymphoma;
rituximab;
cytogenetics
- From:
Chinese Journal of Practical Internal Medicine
2001;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics,therapeutic outcome and prognostic factors of mantle cell lymphoma(MCL)in China.Methods Clinical records of 27 MCL patients were retrospectively analyzed.The results of rituximab combined therapy and conventional therapy regimens were compared,and prognostic factors were analyzed.Results The median age of the 27 patients was 59,with marked male predominance(2.4∶1).There were 88.9% patients with bone marrow involvement at clinical stage Ⅲ～Ⅳ,59.3% with spleen involvement,44.4% with LDH elevated,33.3% with B symptoms and 11.1% with liver involvement.Among the 21 patient with conventional cytogenetic results,7 patients had additional chromosome aberration and 4 patients had more than 4 chromosomes aberration.15/20 patients were misdiagnosed in local hospitals,most of which were diagnosed as CLL/SLL.In 24 untreated patients,the CR/CRu,3 years' OS and PFS in rituximab combined therapy(RCT group)were all significantly higher than those in CT group(87.5% vs 31.3%,87.5% vs 24.1%,70.0% vs 26.9%,P
